AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

Commonly used sulfonylureas were associated with an up to 13% increase in risk for major adverse CV events vs.

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

UBS remains bullish on Merck, reiterating its Buy rating with a $105 price target. This optimism follows Merck's planned $10 ...